Spiralling case numbers have raised fears of diminished protection against new coronavirus variants. Photo: PA
Spiralling case numbers have raised fears of diminished protection against new coronavirus variants. Photo: PA
Spiralling case numbers have raised fears of diminished protection against new coronavirus variants. Photo: PA
Spiralling case numbers have raised fears of diminished protection against new coronavirus variants. Photo: PA

Vaccine dilemma: scientists push for summer booster as Covid-19 surge hits Europe


Nicky Harley
  • English
  • Arabic

With Covid-19 case numbers across Europe surging, experts are predicting a new race that they'd hoped to postpone: another round of booster vaccinations to counter the next wave of the disease as the cooler months approach.

The subvariants of Omicron have so far been milder but far more contagious than earlier mutations, leading to increasing rates of infections and hospital admissions. Case numbers have tripled in the past four weeks.

Professor Danny Altmann, of Imperial College London, told The National that a fourth dose ― constituting a second booster after the first two shots ― towards the end of summer would help slow the pace of transmission in what are the traditional seasonal peaks of autumn/winter in temperate climates.

But, even then, he fears boosters would not be enough, arguing that a “next generation” of vaccines was now desperately required.

“Many in the UK would consider that we’re in a serious BA.5 [Omicron variant] wave,” Prof Altmann said.

“We are a population with waned antibody levels and rather poor cross protection against this variant, and we seem to have settled for 50,000 to 70,000 excess deaths per year.

“So we are not living with it very well. A fourth dose late summer would certainly help, although the strategy is starting to offer diminishing returns. We need the next generation of vaccines.”

Vaccine immunity can wane after three months

Immunity begins to fall between three and six months after each shot, and there are concerns about continuing efficacy given that presently available vaccines were designed to target the original Wuhan virus rather than the new variants.

Omicron subvariant BA.5 is spreading across Europe, with the 53 countries in the WHO European region currently registering about 500,000 cases daily, up from about 150,000 cases a day at the end of May.

"As countries across the European region have lifted the social measures that were previously in place, the virus will transmit at high levels over the summer," WHO Europe regional director Hans Kluge said.

"This virus won't go away just because countries stop looking for it. It's still spreading, it's still changing, and it's still taking lives."

There are currently around 500 deaths per day across Europe - the same level as that recorded not long after the start of the pandemic during the summer of 2020 when countries were in lockdown.

Officials are concerned because though Omicron is milder it is far more transmissible than the strain prevalent two years ago, and the colder weather in which coronavirus thrives is looming.

The past two winters have seen daily death rates rise to up to 5,000 due to seasonal spikes, prompting fears that urgent action needs to happen sooner rather than later.

Should fourth doses be offered to everyone?

Australian health authorities this week recommended that a fourth Covid-19 injection be made available to anyone aged over 30, with a special recommendation for those aged 50-plus to take up the offer.

The UK government’s independent vaccine advisory group, the Joint Committee on Vaccination and Immunisation (JCVI), has recommended that the NHS and care homes prepare for an autumn booster campaign, likely to start in September. In the UK, fourth doses are given only to the over 70s and the most vulnerable.

Dr Stephen Griffin, a virologist at the University of Leeds, says the UK is “ignoring” the warning signs and not preparing for the next big wave.

“What needs to be done and what is being done are two different things,” Dr Griffin told The National.

“The government doesn’t seem minded to push forward vaccines. They have only mentioned boosters for the over-70s in the autumn. It is very clear it is a ‘living with Covid’ strategy.

“We are not in a stable state to say vaccines will give a nominal level of protection now we have got a third wave. To say the pandemic is over, it clearly is not the case. We cannot possibly sustain these new waves of infection. It is still as dangerous with hospital admissions and deaths racking up very quickly as prevalence increases.

“It really is quite difficult to understand. We have not really heard anything from government [about its plans]. We have heard about keeping masks on in hospitals again ― which is a policy that never should have been dropped.

“It appears to be 'let’s ignore it' instead of tackling it. We know enough now not to have to swing between the pendulum of harsh restrictions and opening up."

Dr Griffin wants to see more refined vaccines given more often and warns that Omicron is dangerous. There have, he says, been three waves in the past six months, with the latest "pretty devastating" one responsible for 1,000 hospital admissions a day.

“There are signs this variant can be more nasty and we have to look after our whole population. Omicron has killed more people in the UK than Delta," he said.

“We know this virus is incredibly infectious. Antibodies can drop after three to six months. The answer is to give more vaccines more often at a time when they are waning and when the virus is coming and to pre-empt a new wave, but this is hard to do when new waves are coming every few months.”

Fourth dose boosts immunity more effectively than third dose

Research in the UK shows that a fourth Covid-19 dose increases antibodies to a higher level than that of a third shot.

“These results underline the benefits of the most vulnerable people receiving current [second] boosters and gives confidence for any prospective autumn booster programme in the UK, if the JCVI considers it is needed at that time,” said the director of the NIHR Southampton Clinical Research Facility, Professor Saul Faust, who led the research.

“We knew that it was important to offer a fourth dose to those most vulnerable earlier in the year,” said Professor Andrew Ustianowski, NIHR clinical lead for the Covid-19 vaccination programme and joint national infection specialty lead.

“These new study findings support that decision and provide the public with the confidence that fourth doses are both safe and even more effective than third doses at boosting immunity against Covid-19."

The team is also investigating the optimal interval between second and third doses of vaccines.

Do we need Omicron-specific vaccines?

Prof Faust told The National he is now conducting a study this summer on a vaccine that targets Omicron.

“The UK has already announced plans to look at bivalent boosters and the Cov-boost trial will also be testing the Moderna bivalent vaccine compared to the original Pfizer vaccine in a small sub-study this summer,” he said.

Last week, US regulators recommended changing the design of the vaccines to produce a new booster specifically capable of countering Omicron.

Of the discussions in the US, Prof Altmann pointed out that the immunology was very complex. "Decisions need to be evidence and clinical-trial based, not decided by commercial interests,” he said.

In the UK, Pfizer and Moderna have tweaked their vaccines for Omicron and their trial data is waiting approval from the UK’s Medicines and Healthcare products Regulatory Agency.

The agency needs to assess the safety, quality and effectiveness of the modified shots before the JCVI can consider whether to offer the vaccines in the autumn booster programme.

Dr Griffin believes that by the time any trials have been completed and approved, another variant will already have overtaken its predecessors.

“The US is looking at an Omicron vaccine but the problem is things are moving so quickly we will miss the boat by the time the trials are done. With the boosters, you have to wonder which winter we are actually preparing for,” he said.

“Is there much to gain from an Omicron vaccine, because it doesn’t give protection against anything other than itself. Last year, it was the Delta threat, then along comes Omicron. Who knows where we will be next?

“We have already had three different waves in the last six months. It’s a cat-and-mouse game.”

Many scientists argue that even though the vaccines are not necessarily effective at preventing Omicron infections, they still reduce the risk of severe disease.

With Omicron accounting for more than half of all new UK Covid-19 cases, Prof Susan Hopkins, the chief medical adviser at the UK Health Security Agency, has renewed calls for people eligible for a fourth injection to come forward.

"Our data shows that 17.5 per cent of people aged 75 years and over have not had a vaccine within the past six months, putting them more at risk of severe disease. We urge these people in particular to get up to date."

Given that about 1,000 patients are being admitted to hospital each day with coronavirus, the JCVI has announced a reintroduction of mandatory mask-wearing in hospitals.

It comes just weeks after the mandatory provisions were dropped on June 10.

But with no urgent warnings from the government, Dr Griffin fears that the measure will make little difference, and he has little faith in the ability of the newly appointed health secretary, Steven Barclay, to address the situation.

“If the government says something important, people tend to listen. It’s crazy how many people are so blase, saying they do not need masks, tests or to isolate," he said. "When did this virus stop being what it is?

“There are signs this variant can be more nasty and we have to look after our whole population. It is the responsibility of the government and public health officials. We have no safety net for Covid-19 now. Vaccines are great but not foolproof or infallible and will not see us through this. It is really worrying.

“We are just not doing enough. They are sticking their fingers in their ears and singing 'la-la-la'," he said. "Everyone needs to start planning.”

The specs

Engine: 1.5-litre 4-cylinder petrol

Power: 154bhp

Torque: 250Nm

Transmission: 7-speed automatic with 8-speed sports option 

Price: From Dh79,600

On sale: Now

The biog

Favourite book: Men are from Mars Women are from Venus

Favourite travel destination: Ooty, a hill station in South India

Hobbies: Cooking. Biryani, pepper crab are her signature dishes

Favourite place in UAE: Marjan Island

Infobox

Western Region Asia Cup Qualifier, Al Amerat, Oman

The two finalists advance to the next stage of qualifying, in Malaysia in August

Results

UAE beat Iran by 10 wickets

Kuwait beat Saudi Arabia by eight wickets

Oman beat Bahrain by nine wickets

Qatar beat Maldives by 106 runs

Monday fixtures

UAE v Kuwait, Iran v Saudi Arabia, Oman v Qatar, Maldives v Bahrain

Mrs%20Chatterjee%20Vs%20Norway
%3Cp%3E%3Cstrong%3EDirector%3A%3C%2Fstrong%3E%20Ashima%20Chibber%C2%A0%3C%2Fp%3E%0A%3Cp%3E%3Cstrong%3EStars%3A%3C%2Fstrong%3E%20Rani%20Mukerji%2C%20Anirban%20Bhattacharya%20and%20Jim%20Sarbh%C2%A0%3C%2Fp%3E%0A%3Cp%3E%3Cstrong%3ERating%3A%3C%2Fstrong%3E%202%2F5%3C%2Fp%3E%0A
Islamophobia definition

A widely accepted definition was made by the All Party Parliamentary Group on British Muslims in 2019: “Islamophobia is rooted in racism and is a type of racism that targets expressions of Muslimness or perceived Muslimness.” It further defines it as “inciting hatred or violence against Muslims”.

UAE currency: the story behind the money in your pockets
Avatar: Fire and Ash

Director: James Cameron

Starring: Sam Worthington, Sigourney Weaver, Zoe Saldana

Rating: 4.5/5

Mercer, the investment consulting arm of US services company Marsh & McLennan, expects its wealth division to at least double its assets under management (AUM) in the Middle East as wealth in the region continues to grow despite economic headwinds, a company official said.

Mercer Wealth, which globally has $160 billion in AUM, plans to boost its AUM in the region to $2-$3bn in the next 2-3 years from the present $1bn, said Yasir AbuShaban, a Dubai-based principal with Mercer Wealth.

Within the next two to three years, we are looking at reaching $2 to $3 billion as a conservative estimate and we do see an opportunity to do so,” said Mr AbuShaban.

Mercer does not directly make investments, but allocates clients’ money they have discretion to, to professional asset managers. They also provide advice to clients.

“We have buying power. We can negotiate on their (client’s) behalf with asset managers to provide them lower fees than they otherwise would have to get on their own,” he added.

Mercer Wealth’s clients include sovereign wealth funds, family offices, and insurance companies among others.

From its office in Dubai, Mercer also looks after Africa, India and Turkey, where they also see opportunity for growth.

Wealth creation in Middle East and Africa (MEA) grew 8.5 per cent to $8.1 trillion last year from $7.5tn in 2015, higher than last year’s global average of 6 per cent and the second-highest growth in a region after Asia-Pacific which grew 9.9 per cent, according to consultancy Boston Consulting Group (BCG). In the region, where wealth grew just 1.9 per cent in 2015 compared with 2014, a pickup in oil prices has helped in wealth generation.

BCG is forecasting MEA wealth will rise to $12tn by 2021, growing at an annual average of 8 per cent.

Drivers of wealth generation in the region will be split evenly between new wealth creation and growth of performance of existing assets, according to BCG.

Another general trend in the region is clients’ looking for a comprehensive approach to investing, according to Mr AbuShaban.

“Institutional investors or some of the families are seeing a slowdown in the available capital they have to invest and in that sense they are looking at optimizing the way they manage their portfolios and making sure they are not investing haphazardly and different parts of their investment are working together,” said Mr AbuShaban.

Some clients also have a higher appetite for risk, given the low interest-rate environment that does not provide enough yield for some institutional investors. These clients are keen to invest in illiquid assets, such as private equity and infrastructure.

“What we have seen is a desire for higher returns in what has been a low-return environment specifically in various fixed income or bonds,” he said.

“In this environment, we have seen a de facto increase in the risk that clients are taking in things like illiquid investments, private equity investments, infrastructure and private debt, those kind of investments were higher illiquidity results in incrementally higher returns.”

The Abu Dhabi Investment Authority, one of the largest sovereign wealth funds, said in its 2016 report that has gradually increased its exposure in direct private equity and private credit transactions, mainly in Asian markets and especially in China and India. The authority’s private equity department focused on structured equities owing to “their defensive characteristics.”

COMPANY PROFILE
Name: HyperSpace
 
Started: 2020
 
Founders: Alexander Heller, Rama Allen and Desi Gonzalez
 
Based: Dubai, UAE
 
Sector: Entertainment 
 
Number of staff: 210 
 
Investment raised: $75 million from investors including Galaxy Interactive, Riyadh Season, Sega Ventures and Apis Venture Partners
UAE v Ireland

1st ODI, UAE win by 6 wickets

2nd ODI, January 12

3rd ODI, January 14

4th ODI, January 16

COMPANY%20PROFILE
%3Cp%3E%3Cstrong%3ECompany%20name%3A%20%3C%2Fstrong%3ESupy%0D%3Cbr%3E%3Cstrong%3EStarted%3A%20%3C%2Fstrong%3E2021%0D%3Cbr%3E%3Cstrong%3EFounders%3A%20%3C%2Fstrong%3EDani%20El-Zein%2C%20Yazeed%20bin%20Busayyis%2C%20Ibrahim%20Bou%20Ncoula%0D%3Cbr%3E%3Cstrong%3EBased%3A%20%3C%2Fstrong%3EDubai%0D%3Cbr%3E%3Cstrong%3EIndustry%3A%20%3C%2Fstrong%3EFood%20and%20beverage%2C%20tech%2C%20hospitality%20software%2C%20Saas%0D%3Cbr%3E%3Cstrong%3EFunding%20size%3A%20%3C%2Fstrong%3EBootstrapped%20for%20six%20months%3B%20pre-seed%20round%20of%20%241.5%20million%3B%20seed%20round%20of%20%248%20million%0D%3Cbr%3E%3Cstrong%3EInvestors%3A%20%3C%2Fstrong%3EBeco%20Capital%2C%20Cotu%20Ventures%2C%20Valia%20Ventures%20and%20Global%20Ventures%3C%2Fp%3E%0A
Company%20profile%20
%3Cp%3E%3Cstrong%3EName%3A%20%3C%2Fstrong%3EYodawy%3Cbr%3E%3Cstrong%3EBased%3A%3C%2Fstrong%3E%20Egypt%3Cbr%3E%3Cstrong%3EFounders%3A%20%3C%2Fstrong%3EKarim%20Khashaba%2C%20Sherief%20El-Feky%20and%20Yasser%20AbdelGawad%3Cstrong%3E%3Cbr%3ESector%3A%20%3C%2Fstrong%3EHealthTech%3Cbr%3E%3Cstrong%3ETotal%20funding%3A%20%3C%2Fstrong%3E%2424.5%20million%3Cbr%3E%3Cstrong%3EInvestors%3A%20%3C%2Fstrong%3EAlgebra%20Ventures%2C%20Global%20Ventures%2C%20MEVP%20and%20Delivery%20Hero%20Ventures%2C%20among%20others%3Cstrong%3E%3Cbr%3ENumber%20of%20employees%3A%3C%2Fstrong%3E%20500%3Cbr%3E%3C%2Fp%3E%0A
Updated: June 07, 2023, 4:41 PM